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Abstract
Summary Among 8,822 new female bisphosphonate users,
non-compliant bisphosphonate use was associated with a
45% increased risk of osteoporotic fracture compared to
compliant use (MPR ≥80%). Classifying compliance into
five categories, fracture risk gradually increased with
poorer compliance. These results emphasize the importance
of treatment compliance in obtaining maximal treatment
benefit.
Introduction Bisphosphonates are widely used to treat
osteoporosis and reduce fracture risk. Low compliance is
frequent and will limit treatment benefit.
Methods New female users of alendronate or risedronate
between 1999–2004, aged ≥45 years were identified from
PHARMO-RLS, including drug-dispensing and hospitali-
zation data of ≥2 million residents of the Netherlands.
Patients were followed until first hospitalisation for an
osteoporotic fracture, death, or end of study period. Compli-
ance with bisphosphonates during follow-up was measured
over 90-day intervals using Medication Possession Ratio
(MPR). The association between compliance and fracture risk
was analyzed using time-dependent Cox-regression.
Results The study cohort included 8,822 new female
bisphosphonate users, contributing in total 22,484 person-years
of follow-up. During follow-up, 176 osteoporotic fractures
occurred (excluding the first six months). Non-compliant
bisphosphonate use was associated with a 45% increased
fracture risk compared to compliant use (MPR ≥80%).
Classifying compliance into five categories, fracture risk
gradually increased with poorer compliance (p-value <0.05
fortrend). A MPR <20%wasassociated with an 80% increased
fracture risk compared to a MPR ≥90%.
Conclusions These results show a statistically significant
association between level of compliance with bisphospho-
nates and level of fracture risk, emphasizing the importance
of treatment compliance in obtaining maximal treatment
benefit.
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Introduction
Osteoporosis is a systemic condition characterized by low
bone mass and microarchitectural deterioration of bone
tissue, leading to enhanced bone fragility and, consequent-
ly, an increased fracture risk [1]. Osteoporosis has clinical
and public health importance because osteoporotic fractures
are one of the most common causes of disability and a
major contributor to medical costs in many regions of the
world [2]. Bisphosphonates are potent inhibitors of the
osteoclast-mediated resorption of bone and widely used to
treat osteoporosis and reduce the risk of osteoporotic
fractures [3].
Long-term therapy with bisphosphonates is required to
realise the full benefits of this treatment [3, 4]. This is
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risk of fractures was reduced by 26% after one year
persistent bisphosphonate use and up to 32% after two
year persistent use [5]. However, in daily clinical practice,
50% to 75% of patients discontinue bisphosphonate use
already in the first year of therapy [5–8]. Moreover, non-
compliance with bisphosphonates has also been reported to
be a frequent issue, with rates varying from 35% to 65%
[6, 9]. Reasons for low compliance with bisphosphonate
treatment are the stringent regimen to minimize the risk of
oesophageal irritation, the existence of drug-related gastro-
intestinal side effects, and the fact that osteoporosis is often
asymptomatic in early stages [10]. Caro et al. showed that
patients who were compliant with their osteoporosis
medication, including bisphosphonates, estrogens and cal-
citonin, experienced a 16% lower fracture rate compared to
non-compliant users [11]. The objective of this study was to
investigate the risk of osteoporotic fractures associated with
low compliance with bisphosphonates in more detail. In
addition to dichotomizing compliance, we also classified
compliance into five categories.
Patients and methods
Setting
Data were obtained from the PHARMO Record Linkage
System (PHARMO RLS) which includes several databases,
among which drug dispensing and hospitalization data of
more than two million residents of the Netherlands. The
drug dispensing histories contain data on the dispensed
drug, the type of prescriber, the dispensing date, the amount
dispensed, the prescribed dose regimens, and the duration
of use. All drugs are coded according to the Anatomical
Therapeutic Chemical (ATC) Classification. The hospital
records include detailed information concerning the primary
and secondary diagnoses, procedures, and dates of hospital
admission and discharge. All diagnoses are coded accord-
ing to the International Classification of Diseases, 9th
Revision, Clinical Modification (ICD-9-CM).
Study cohort
The source population included all new users of bisphos-
phonates in the period from January 1999 until July 2004.
These patients were not dispensed any anti-osteoporotic
drugs (bisphosphonates, raloxifene, tibolone, estrogens,
hormone replacement therapy, calcitonin or teriparatide)
for at least one year before their first bisphosphonate
dispensing. All female new users of alendronate (10 mg
daily or 70 mg weekly) or risedronate (5 mg daily or 35 mg
weekly) (i.e. the dosages indicated for the prevention or
treatment of postmenopausal osteoporosis), aged ≥45 years
or with diagnosed postmenopausal osteoporosis (ICD-9-CM
code 733.01), without gaps in registration in PHARMO RLS,
and with a registration of at least one year before and one year
after starting bisphosphonate treatment were included in the
study cohort.
All study patients were followed from the first
bisphosphonate dispensing until the occurrence of the
outcome of interest, death, end of registration in PHARMO
RLS or end of the study period, whichever event was
earliest.
Compliance
Compliance with bisphosphonates during follow-up may
change and was measured over 90-day intervals using the
Medication Possession Ratio (MPR). MPR was defined as
the sum of days’ supply of all alendronate and risedronate
dispensings during or overlapping the 90-day interval
divided by 90 potential days of bisphosphonate therapy.
For each dispensing only the days’ supply covering a
specific interval were counted. E.g. of a 100-days supply
dispensed at follow-up day 60, only 30 days were counted
when calculating the MPR over the first interval (day 0–90) and
70 days for the MPR over the second interval (day 91–180).
The maximum value of a MPR was set at 1. Subdividing
follow-up in larger intervals was assumed too rough and
subdividing in smaller intervals was not feasible regarding the
usual prescriptionl e n g t ho f9 0d a y s .
Osteoporotic fractures
The outcome variable osteoporotic fracture was defined as
hospitalisation for an osteoporotic fracture during follow-
up. Hospitalisations were selected based on primary
discharge diagnosis for probable (ICD-9-CM codes 805.2
(vertebral thoracic), 805.4 (vertebral lumbar), 820 (proximal
femur), 812 (proximal humerus), 813.4 (distal radius/ulna),
814 (carpus)) or possible (ICD-9-CM codes 823.0 (proximal
tibia/fibula), 807.0 (rib), 807.2 (sternum), 808.0 (pelvis))
osteoporotic fractures.
Covariates
For all patients, a history of osteoporotic fracture was
assessed. Furthermore, we determined use of non-steroidal
anti-inflammatory drugs, analgesics, benzodiazepines and
antidepressants in the year after starting bisphosphonate
treatment as these drugs are associated with an increased
risk of fractures [12–14]. Similarly, we assessed use of
thiazide diuretics, ß-blockers and statins in the year after
start as these drugs are associated with a reduced risk of
fractures [15–17].
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The association between low compliance with bisphos-
phonates and the risk of fractures was analysed univariately
and multivariately using time-dependent Cox regression
analysis to account for changing compliance over time. In
this analysis, at the time of each fracture, the cumulative
compliance up to and including the corresponding 90-day
interval of women who had experienced a fracture was
compared to the cumulative compliance of those women
who remained fracture-free at this time. The cumulative
compliance of the fracture-free patients was measured up to
the interval of corresponding fracture.
In a first analysis, compliance was dichotomized and a
MPR <80%, i.e. non-compliant bisphosphonate use was
compared to a MPR ≥80%, i.e. compliant use. In a second
analysis, compliance was classified into five categories:
<20%, 20–49%, 50–69%, 70–89% and ≥90% (reference).
A Wald test for trend was performed. Assuming that the
effect of bisphosphonates is not immediate, and in line with
Caro et al. [11], fractures occurring in the first 182 days of
follow-up were excluded from the analyses. In a sub-
analysis, this exclusion period was varied. Furthermore, an
additional analysis was performed excluding women with
only one bisphoshonate dispensing during follow-up; in
these patients it is less sure that they actually used the drug.
The multiple regression models included age, history of
fracture and all covariates that were univariately associated
with the risk of fractures and significantly contributed to the
multivariate model, i.e. inclusion of the covariate resulted
in a change of the compliance hazard ratio (HR) of 5% or
over, starting with the most potent covariate. HRs and 95%
confidence intervals (CI) were estimated using SAS V8.2
UNIX (Cary, NC, USA).
Results
The study cohort included 8,822 new female users of daily
or weekly alendronate or risedronate, who contributed a
total of 22,484 person-years of follow-up during the study
period. More than half of the patients were older than
70 years of age (n=4,708, 53%) and about one quarter of
the patients used corticosteroids (irrespective of quantity)
(Table 1). The first bisphosphonate was mainly prescribed
by the general practitioner (64%). Only 197 patients (2%)
were hospitalized for an osteoporotic fracture in the year
before starting treatment.
During follow-up, 216 patients (2%) experienced an
osteoporotic fracture, of which 40 patients during the first
six months and 78 during the first year. About two third of
all osteoporotic fractures were located at the proximal
femur.
The percentage of patients with a MPR < 80% (i.e. non-
compliant patients) increased from 34% (3,018/8,822) after
six months of follow-up to 42% (3,743/8,822) after one year,
51% (3,014/5,883) after two years and 60% (2,149/3,615)
after three years of follow-up. Subdividing MPR in classes
(Fig.1), the majority of patients either had a MPR ≥90% or a
MPR <20%, with the first group decreasing and the latter
group increasing over time.
Dichotomizing compliance, a MPR <80%, i.e. non-
compliant bisphosphonate use was associated with a 40%
increased risk of osteoporotic fracture more than six months
Table 1 General characteristics of new bisphosphonate users between 1 January 1999 and 30 June 2004 (N=8,822)
Characteristic N%
Age class (years) 45–54 889 10.1
55–69 3,225 36.5
≥70 4,708 53.4
Mean age (years) ± sd 69.4±10.3
Year of start 1999 / 2000 2,250 25.5
2001 / 2002 2,769 31.4
2003 / 2004 3,803 43.1
Initial bisphosphonate Daily bisphosphonate 4,222 47.9
Weekly bisphosphonate 4,600 52.1
First prescriber General practitioner 5,704 64.7
Internist, rheumatologist, orthopedist 2,313 26.2
Other prescribers 805 9.1
Hospitalization for an osteoporotic fracture in the year before start 197 2.2
Use of corticosteroids in the year before start (irrespective of quantity) 2,389 27.1
Follow-up time (months) 12–23 2,939 33.3
24–35 2,268 25.7
≥36 3,615 41.0
Osteoporos Int (2008) 19:511–517 513after starting treatment (HR 1.41 95% CI 1.04–1.91,
adjusted for age and history of fracture (see Table 2 for
association between co-variates and fracture risk)) com-
pared to a MPR ≥80%, i.e. compliant use. Varying the
exclusion period, i.e. excluding fractures occurring in the
first year of follow-up or including all fractures during
follow-up, yielded similar adjusted increased risks (HR
1.50; 95%CI 1.06–2.13 and HR 1.45; 95%CI 1.10–1.91,
respectively). Excluding women who received only one
bisphosphonate dispensing during follow-up also did not
change the results (adjusted HR 1.45; 95% CI 1.05–1.99,
based on 156 fracture patients and 7,758 fracture-free
patients).
Classifying compliance into five categories, fracture risk
gradually increased with poorer compliance (p-value <0.05
for trend). Compared to a MPR ≥90%, the adjusted risk of
fracture increased from 1.2 times for a MPR between 50%
and 90% to 1.8 times for a MPR less than 20% (Fig. 2).
Discussion
This study indicates that non-compliant bisphosphonate
users had an approximately 50% higher likelihood of
osteoporotic fracture compared to compliant users. Classi-
fying compliance into five categories, fracture risk gradu-
ally increased with poorer compliance to an 80% risk
increase with very low compliance compared to very high
compliance. These results emphasize the importance of
treatment compliance in obtaining maximal treatment
benefit.
To quantify the loss of treatment benefit with low
compliance, information on fracture risk in women not
treated with bisphosphonates is necessary. The above
mentioned percentage risk increases are compared to
compliant use and cannot be translated into percentage loss
of treatment benefit. We chose not to use untreated patients
as reference because of the heterogeneity of patterns of
treatment use that exist within this group. In a meta-analysis
of 11 trials of alendronate for the treatment of postmeno-
pausal osteoporosis, a consistent 50% reduction in fracture
risk was seen compared to placebo [18]. For risedronate, a
meta-analysis of 8 trials revealed a 25 to 35% reduction in
fracture risk compared to placebo [19]. In other words,
untreated women are 1.5 to 2 times as likely to experience a
fracture compared to women using bisphosphonates.
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Fig. 1 Compliance with bisphosphonates, classified in five MPR
categories, after six months, one year, two years and three years of
follow-up. MPR: medication possession ratio
Table 2 Association between co-variates and fracture risk more than six months after starting treatment
Fracture patients (N) Fracture-free patients (N)
N%N % H R crude 95% CI
Total 176 100 8,606 100
Age (years) at start
45–54 7 4.0 879 10.2 1.00 reference
55–69 29 16.5 3,189 37.1 1.16 0.51–2.66
≥70 140 79.5 4,538 52.7 4.28 2.00–9.15
Year of start
1999/2000 86 48.9 2,158 25.1 1.68 1.04–2.71
2001/2002 63 35.8 2,691 31.3 1.55 0.97–2.49
2003/2004 27 15.3 3,757 43.6 1.00 reference
History of osteoporotic fracture 5 2.8 190 2.2 1.52 0.63–3.70
Comedication in the year after start
1
Analgesics 68 38.6 2,136 24.8 1.82 1.34–2.46
Benzodiazepines 80 45.5 3,324 38.6 1.30 0.96–1.74
Antidepressants 29 16.5 1,046 12.2 1.52 1.02–2.26
ß-blockers 47 26.7 1,929 22.4 1.35 0.97–1.89
HR: hazard ratio, CI: confidence interval
1 Univariate non-significant comedications (i.e. non-steroidal anti-inflammatory drugs, thiazides and statins) are not shown.
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are comparable to the treated patients in trials, the 1.6 to 1.8
times increased fracture risk we observed with a MPR
<50% can be translated into a 80 to 100% loss of treatment
benefit. Apparently, patients with the lowest compliance are
essentially comparable to non-treated patients.
At present, in addition to Caro et al., others have
reported on the relationship between compliance with
bisphosphonates and fracture risk [11, 20, 21]. Siris et al.
[20] found a relative fracture risk reduction of 25% with
compliant use of alendronate or risedronate, i.e. a 33% risk
increase with non-compliant use. There was a progressive
relationship between compliance and fracture risk reduc-
tion, commencing at a MPR around 50% and becoming
more pronounced at a MPR ≥75%. This finding, like our
results, suggests that low-compliant patients gain only
marginal benefit from bisphosphonate therapy. Among
women starting drug therapy for osteoporosis (of which
two-third bisphosphonates) Weycker et al. [21] found that
compared to women with a MPR <30%, the odds of
fracture was similar (1.02) for women with a MPR between
30 and 69% and women with a MPR between 70 and 89%,
but lower (0.70) for women with a MPR ≥90%. The latter
corresponds to a 1.4 times increased risk of fracture with a
MPR <30% compared to a MPR ≥90%. Caro et al. [11]
reported that compared to a MPR >90%, fracture risk was
significantly increased at lower compliance levels, i.e. up to
1.4 times with a MPR ≤50%. However, it is not clear
whether this effect was gradual. In a study population of
mainly users of hormone replacement therapy, Huybrechts
et al. [22] found that compared to women with a MPR
≥90%, fracture risk was similar (HR 1.09) for women with
a MPR between 80 and 90%, but higher for women with a
MPR between 50 and 80% and women with a MPR <50%
(HR 1.18 and 1.21, respectively). Our associations are
about similar than reported by Siris et al., but stronger than
found by Caro et al., Weycker et al. and Huybrechts et al.
The most likely explanation for this is that our and Siris’
study population was restricted to bisphosphonate users,
while the others also included users of other, less potent anti-
osteoporotic drugs (30% to 65% of the study population).
There is a previous PHARMO study on bisphosphonate
use and risk of fractures, using persistence [5]. Besides a
different measure of drug exposure, the current study differs
from this previous study in that the study period was
extended, different inclusion criteria were applied and new
patients were included besides previously studied patients.
Although persistence and compliance are measured differ-
ently, with persistence referring to the duration of uninter-
rupted drug use, they are closely related. Patients classified
as non-compliant would also have been classified as non-
persistent and vice versa. The results of our current study
are in line with our previous study in which the risk of
fractures was reduced by 26% after one year persistent
bisphosphonate use and up to 32% after two years of
persistent use [5]. Similarly, Gold et al [23] reported that
persistent bisphosphonate use for at least 6 months was
associated with a 26% lower fracture risk. Expressing these
results the other way around, non-persistent bisphosphonate
use is associated with an about 40% fracture risk increase.
Among a population of mainly users of hormone replace-
ment therapy, one year of uninterrupted therapy reduced the
likelihood of fractures with significant odds ratios of 0.38
for hip fractures and 0.60 for vertebral fractures [7].
Our analyses may be limited by some issues common to
observational database research in daily clinical practice.
Most importantly, although we considered a large number
of known confounders in our analyses, including history of
fractures, there may be other confounding factors for which
information was not available, such as bone mineral density
(BMD). BMD is an important determinant of fracture risk
[24] and BMD testing has been shown to be positively
associated with persistence and compliance [25, 26].
Consequently, the results of our analyses are likely to be
conservative in the sense that compliant patients may have
had an increased fracture risk because of low BMD, and
history of fractures only partially controlled for this.
Furthermore, it is possible that patients have started using
other anti-osteoporotic drugs, e.g. raloxifene, during fol-
low-up and stopped bisphosphonate use. This means that
part of the patients who were non-compliant with
bisphosphonates may have been protected against fractures
by another anti-osteoporotic drug and the observed
increased fracture risk with non-compliant bisphosphonate
use therefore may be underestimated. However, we know
from our database that this concerns only about 7% of
patients in the first year of bisphosphonate treatment. In
addition, compliance with treatment was based on dispens-
ing data. As it is unknown whether a patient actually used
the drug, compliance may have been overestimated.
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Fig. 2 The relationship between compliance with bisphosphonates,
classified in five MPR categories, and fracture risk more than half a
year after starting treatment. HRs are adjusted for age and history of
fracture and are compared to a MPR ≥90%. MPR: medication
possession ratio, HR: hazard ratio, CI: confidence interval
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tion refills do take their medication. Excluding women who
filled only one bisphosphonate dispensing during follow-up
from the analyses did not change the results. Another
limitation relates to the classified analysis. With the use of
five compliance categories studying a trend is possible but
it does not give information on the point at which there is a
significant shift in fracture risk. Ideally, 10% MPR
categories should be used. However, patient numbers per
10% MPR categories (data not shown) did not allow for
this detailed analysis.
To increase the treatment benefit of bisphosphonates,
compliance should be improved. Related to the inconve-
nient, stringent intake regimen, dosing frequency is an
important determinant of compliance with bisphosphonates.
In recent earlier studies, once-weekly dosing was associated
with better compliance and persistence compared to daily
dosing. However, even with the weekly regimen, compli-
ance and persistence were suboptimal in about half of the
patients [6, 8, 9]. Bisphosphonates with less frequent
dosing regimes than weekly, e.g. monthly or three-monthly
ibandronate or annual zolendronate, are either available yet
or upcoming and may further improve compliance and
therefore treatment benefit. In a cross-over trial, women
with postmenopausal osteoporosis preferred once-monthly
ibandronate therapy and found it more convenient than
once-weekly alendronate therapy [27]. There are no data
yet on the actual impact of this once-monthly, and other
formulations on compliance with bisphosphonate therapy
and reduction of fracture risk in daily practice. Other keys
to improve compliance are e.g. healthcare provider - patient
communication and continuous reinforcement of the im-
portance of treatment. Reminder systems may help the
patient comply with therapy, especially with infrequent
dosing regimes. However, results from a review show that
current methods of improving patient compliance for
several chronic health problems are mostly not very
successful [28]. Furthermore, although a number of
demographic and clinical variables are associated with
compliance with bisphosphonates these predictors, either
individually or together, have been shown to have low
predictive value for identifying patients who will become
non-compliant [25].
In conclusion, the results of this study show a statisti-
cally significant association between level of compliance
with bisphosphonates and level of fracture risk, emphasiz-
ing the importance of treatment compliance in obtaining
maximal bone protection.
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